Gene · 3799
Papers2,390
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
161 to 180 of 2,390
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Spitz Tumors and Melanoma in the Genomic Age: A Retrospective Look at Ackerman's Conundrum. | Cancers (Basel) | 2023 | 38136379 | PubTator, text mining | PubMed |
| Whole-genome sequencing reveals the molecular implications of the stepwise progression of lung adenocarcinoma. | Nat Commun | 2023 | 38102134 | PubTator, text mining | PubMed |
| Cerebrospinal Fluid Concentration of the RET Inhibitor Pralsetinib: A Case Report. | Case Rep Oncol | 2023 | 38094038 | PubTator, text mining | PubMed |
| Case report: ALK-positive histiocytosis presented as bilateral synchronous breast masses with long-term remission on crizotinib. | Front Med (Lausanne) | 2023 | 38093982 | PubTator, text mining | PubMed |
| Primary resistance to ALK inhibitors in KLC1/ALK-rearranged pleural metastatic lung adenocarcinoma: a case report. | Transl Lung Cancer Res | 2023 | 38090529 | PubTator, text mining | PubMed |
| Receptor tyrosine kinases: biological functions and anticancer targeted therapy. | MedComm (2020) | 2023 | 38077251 | PubTator, text mining | PubMed |
| Molecular profiling and feasibility using a comprehensive hybrid capture panel on a consecutive series of non-small-cell lung cancer patients from a single centre. | ESMO Open | 2023 | 38070435 | PubTator, text mining | PubMed |
| Whole-exome sequencing explored mechanism of selpercatinib resistance in RET-rearranged lung adenocarcinoma transformation into small-cell lung cancer: a case report. | BMC Pulm Med | 2023 | 38057798 | PubTator, text mining | PubMed |
| Sustained Clinical Response to 4th-Line Therapy with Selpercatinib in RET Fusion-Positive Combined Small Cell Lung Cancer. | Onco Targets Ther | 2023 | 38050583 | PubTator, text mining | PubMed |
| [Mutation pedigree and treatment selection of Erdheim-Chester disease]. | Zhonghua Xue Ye Xue Za Zhi | 2023 | 38049347 | PubTator, text mining | PubMed |
| Salvage Therapy With Selpercatinib for RET-Rearranged NSCLC With Pralsetinib-Related Pneumonitis and Leptomeningeal Disease: A Case Report. | JTO Clin Res Rep | 2023 | 38034820 | PubTator, text mining | PubMed |
| Two case reports: EML4-ALK rearrangement large cell neuroendocrine carcinoma and literature review. | Front Oncol | 2023 | 38023218 | PubTator, text mining | PubMed |
| Case Report: A novel FGFR1 fusion in acute B-lymphoblastic leukemia identified by RNA sequencing. | Front Oncol | 2023 | 38023217 | PubTator, text mining | PubMed |
| Relationship between driver gene mutations and clinical pathological characteristics in older lung adenocarcinoma. | Front Oncol | 2023 | 38023198 | PubTator, text mining | PubMed |
| [Drug Resistance Mechanism and Therapeutic Strategy of Targeted Therapy of Non-small Cell Lung Cancer with MET Alterations]. | Zhongguo Fei Ai Za Zhi | 2023 | 37985154 | PubTator, text mining | PubMed |
| [Chinese Expert Consensus on the Clinical Practice of Non-small Cell Lung Cancer Fusion Gene Detection Based on RNA-based NGS]. | Zhongguo Fei Ai Za Zhi | 2023 | 37985137 | PubTator, text mining | PubMed |
| Understanding the feasibility of chemotherapeutic and immunotherapeutic targets against non-small cell lung cancers: an update of resistant responses and recent combinatorial therapies. | Explor Target Antitumor Ther | 2023 | 37970206 | PubTator, text mining | PubMed |
| Comprehensive next-generation sequencing reveals double primary colorectal carcinoma missed by diagnostic imaging: A case report. | World J Gastrointest Oncol | 2023 | 37969415 | PubTator, text mining | PubMed |
| Genetic and Lifestyle-Related Factors Influencing Serum Hyper-Propionylcarnitine Concentrations and Their Association with Metabolic Syndrome and Cardiovascular Disease Risk. | Int J Mol Sci | 2023 | 37958793 | PubTator, text mining | PubMed |
| Confined-microtubule assembly shapes three-dimensional cell wall structures in xylem vessels. | Nat Commun | 2023 | 37957173 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3799/papers?page=9